SAN DIEGO, May 11 /PRNewswire-FirstCall/ -- MicroIslet, Inc. , a biotechnology company engaged in the research, development and commercialization of patented technologies in transplantation therapy for people with insulin-dependent diabetes, announced today its scheduled presentation at Rodman & Renshaw’s 3rd Annual Global Healthcare Conference on Monday, May 15, at 5:25 p.m. local time in Monte Carlo, Monaco. This conference will be held at the Le Meridien Beach Plaza Hotel in Monte Carlo.
John F. Steel IV, MicroIslet’s Director of Corporate Communications and a member of its Board of Directors, will update conference attendees on preclinical advances in the Company’s proprietary approach to treating insulin-dependent diabetes through minimally invasive transplantation of microencapsulated, insulin-producing porcine islets. This therapeutic approach is designed to replace the need for frequent insulin injections and blood monitoring on the part of insulin-dependent diabetics. MicroIslet enjoys exclusive access to the Mayo Foundation’s designated pathogen-free pig facility for the treatment of diabetes, providing the Company with an existing supply of suitable cells. Further, the Company’s proprietary microencapsulation techniques are designed to obviate the need for immunosuppressive therapy to prevent the recipient’s immune rejection of the transplanted insulin-producing tissues.
About MicroIslet
MicroIslet is a biotechnology company engaged in the research, development, and commercialization of patented technologies in the field of transplantation therapy for people with insulin-dependent diabetes. MicroIslet’s patented islet transplantation technology, exclusively licensed from Duke University, includes methods for isolating, culturing, cryopreservation, and immuno-protection (microencapsulation) of islet cells. MicroIslet is working to develop and commercialize a first product, called MicroIslet-P(TM), a microencapsulated porcine islet cell suspension that will be used for transplantation in patients with insulin-dependent diabetes. Additional information about MicroIslet can be found at www.microislet.com.
Except for the historical information contained herein, the matters set forth in this press release, including the implication and interpretation of preliminary data, the expectation of development of new therapeutic products and the impact of MicroIslet’s products on diabetes patients, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including MicroIslet’s ability to continue as a going concern, the risks and uncertainties inherent in medical treatment discovery, development and commercialization, the risks and uncertainties associated with MicroIslet’s early stage xenotransplantation technologies, the risks and uncertainties of governmental approvals and regulation, dependence on the Mayo Foundation for Medical Education and Research as a sole source supplier of animal parts for pre-clinical and clinical studies, MicroIslet’s need to raise substantial additional capital to proceed through human clinical trials and bring any product to market, the risks that MicroIslet’s competitors will develop or market technologies or products that are more effective or commercially attractive than MicroIslet’s products, and other risks detailed from time to time in MicroIslet’s most recent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. MicroIslet disclaims any intent or obligation to update these forward-looking statements.
For more information, please visit our Web site at www.microislet.com. For further information, contact: Kevin A. Hainley, MicroIslet, Inc. 858-657-0287, info@microislet.com Sean Collins, Partner CCG Investor Relations & Strategic Communications 310-231-8600 ext. 202 ISIN US59507Q1067
MicroIslet, Inc.
CONTACT: Kevin A. Hainley of MicroIslet, Inc., +1-858-657-0287,info@microislet.com; or Sean Collins, Partner, CCG Investor Relations &Strategic Communications, +1-310-231-8600, ext. 202, for MicroIslet, Inc.
Web site: http://www.microislet.com/
